Author Page for Ariel Dora Stern

The Impact of the Entry of Biosimilars: Evidence from Europe

Morton, Fiona M. Scott, Ariel Dora Stern, and Scott Stern. "The impact of the entry of biosimilars: evidence from Europe." Review of Industrial Organization 53, no. 1 (2018): 173-210.

Number of pages: 71 Posted: 24 Jul 2016 Last Revised: 04 May 2019

Fiona M. Scott Morton, Ariel Dora Stern and Scott Stern

Yale School of Management, University of Potsdam - Hasso Plattner Institute (HPI) and Massachusetts Institute of Technology (MIT) - Sloan School of Management

Downloads 472 (127,773)

Citation 10

Abstract:

2.

Responding Strategically to Competitors' Failures: Evidence from Medical Device Recalls & New Product Submissions

Harvard Business School Working Paper 19-028 , Georgetown McDonough School of Business Research Paper No. 3251630

Number of pages: 35 Posted: 12 Oct 2018 Last Revised: 19 May 2022

George Ball, Jeffrey T. Macher and Ariel Dora Stern

Indiana University - Kelley School of Business, Georgetown University - McDonough School of Business and University of Potsdam - Hasso Plattner Institute (HPI)

Downloads 429 (143,236)

Citation 3

Abstract:

3.

How Important is Editorial Gatekeeping? Evidence from Top Biomedical Journals

Harvard Business School Technology & Operations Mgt. Unit Working Paper No. 22-011, Harvard Business School Entrepreneurial Management Working Paper No. 22-011

Number of pages: 45 Posted: 12 Jul 2021 Last Revised: 16 Feb 2023

Joshua Krieger, Kyle Myers and Ariel Dora Stern

Harvard University - Business School (HBS), Harvard University - Technology & Operations Management Unit and University of Potsdam - Hasso Plattner Institute (HPI)

Downloads 196 (325,908)

Citation 2

Abstract:

4.

Pioneer (Dis-)advantages in Markets for Technology

Harvard Business School Working Paper No. 19-043

Number of pages: 42 Posted: 01 May 2019 Last Revised: 18 Mar 2020

Moritz Fischer, Joachim Henkel and Ariel Dora Stern

Technische Universität München (TUM), TUM School of Management,Technical University of Munich and University of Potsdam - Hasso Plattner Institute (HPI)

Downloads 196 (322,836)

Abstract:

5.

Innovation Under Regulatory Uncertainty: Evidence from Medical Technology

Stern, A.D., Innovation under Regulatory Uncertainty: Evidence from Medical Technology, Journal of Public Economics. Final version published online: 06-Dec-2016. DOI information: 10.1016/j.jpubeco.2016.11.010, Journal of Public Economics, Vol. 145, 2017

Number of pages: 20 Posted: 17 Oct 2016 Last Revised: 13 Aug 2018

Ariel Dora Stern

University of Potsdam - Hasso Plattner Institute (HPI)

Downloads 118 (493,082)

Citation 12

Abstract:

6.

Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation

Downloads 100 (556,632)

Citation 4

2

Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation

HKS Working Paper No. RWP22-024

Number of pages: 91 Posted: 09 Dec 2022 Last Revised: 17 Aug 2024

Amitabh Chandra, Jennifer L. Kao, Kathleen Miller and Ariel Dora Stern

Harvard University - Harvard Kennedy School (HKS), UCLA Anderson, U.S. Food and Drug Administration and University of Potsdam - Hasso Plattner Institute (HPI)

Downloads 89 (606,815)

Citation 1

Abstract:

Regulatory Incentives for Innovation: The Fda's Breakthrough Therapy Designation

NBER Working Paper No. w30712

Number of pages: 89 Posted: 06 Dec 2022 Last Revised: 02 Jun 2023

Amitabh Chandra, Jennifer L. Kao, Kathleen Miller and Ariel Dora Stern

Harvard University - Harvard Kennedy School (HKS), UCLA Anderson, U.S. Food and Drug Administration and University of Potsdam - Hasso Plattner Institute (HPI)

Downloads 11 (1,261,260)

Citation 3

Abstract:

7.

Physician Beliefs and Patient Preferences: A New Look at Regional Variation in Health Care Spending

NBER Working Paper No. w19320

Number of pages: 64 Posted: 17 Aug 2013 Last Revised: 17 Apr 2022

David M. Cutler, Jonathan S. Skinner, Ariel Dora Stern and David Wennberg

Harvard University - Department of Economics, Dartmouth College - Department of Economics, University of Potsdam - Hasso Plattner Institute (HPI) and Geisel School of Medicine at Dartmouth

Downloads 79 (642,990)

Citation 49

Abstract:

8.

Characterizing the Drug Development Pipeline for Precision Medicines

NBER Working Paper No. w24026

Number of pages: 70 Posted: 20 Nov 2017 Last Revised: 24 Feb 2023

Amitabh Chandra, Craig L. Garthwaite and Ariel Dora Stern

Harvard University - Harvard Kennedy School (HKS), Northwestern University - Department of Management & Strategy and University of Potsdam - Hasso Plattner Institute (HPI)

Downloads 42 (871,258)

Citation 3

Abstract:

9.

Which Markets (Don'T) Drive Pharmaceutical Innovation? Evidence from U.S. Medicaid Expansions

NBER Working Paper No. w28755

Number of pages: 47 Posted: 10 May 2021 Last Revised: 26 Jan 2023

Craig Garthwaite, Rebecca Sachs and Ariel Dora Stern

Northwestern University, George Washington University - Law School and University of Potsdam - Hasso Plattner Institute (HPI)

Downloads 23 (1,064,319)

Abstract:

10.

The Regulation of Medical Ai: Policy Approaches, Data, and Innovation Incentives

NBER Working Paper No. w30639

Number of pages: 26 Posted: 05 Dec 2022 Last Revised: 14 Apr 2023

Ariel Dora Stern

University of Potsdam - Hasso Plattner Institute (HPI)

Downloads 19 (1,114,327)

Abstract:

11.

Germany’s Digital Health Reforms in the COVID-19 Era: Lessons and Opportunities for Other Countries

npj Digit. Med. 3, 94 (2020). https://doi.org/10.1038/s41746-020-0306-7

Posted: 09 Jul 2021

Sara Gerke, Ariel Dora Stern and Timo Minssen

University of Illinois College of Law, University of Potsdam - Hasso Plattner Institute (HPI) and University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law

Ariel Dora Stern

University of Potsdam - Hasso Plattner Institute (HPI)

Harvard Business School

Associate Professor

11

1,674

Top 16,092

83

Scholarly Papers (11)

The Impact of the Entry of Biosimilars: Evidence from Europe

Abstract:

Responding Strategically to Competitors' Failures: Evidence from Medical Device Recalls & New Product Submissions

Abstract:

How Important is Editorial Gatekeeping? Evidence from Top Biomedical Journals

Abstract:

Pioneer (Dis-)advantages in Markets for Technology

Abstract:

Innovation Under Regulatory Uncertainty: Evidence from Medical Technology

Abstract:

Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation

Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation

Abstract:

Regulatory Incentives for Innovation: The Fda's Breakthrough Therapy Designation

Abstract:

Physician Beliefs and Patient Preferences: A New Look at Regional Variation in Health Care Spending

Abstract:

Characterizing the Drug Development Pipeline for Precision Medicines

Abstract:

Which Markets (Don'T) Drive Pharmaceutical Innovation? Evidence from U.S. Medicaid Expansions

Abstract:

The Regulation of Medical Ai: Policy Approaches, Data, and Innovation Incentives

Abstract:

Germany’s Digital Health Reforms in the COVID-19 Era: Lessons and Opportunities for Other Countries

Abstract: